natgillin/translations-raw huggingface dataset:
injections, patches and implants - rifampin - to treat tuberculosis - warfarin - to prevent and treat blood clots forming in the legs, lungs, brain and heart. 
motenj razpoloženja in preprečevanje migrene - sildenafil - za zdravljenje motnje erekcije - kontracepcijska sredstva - uporabljajo se za preprečevanje nosečnosti in vključujejo peroralne kontraceptive (kontracepcijske tabletke), kontracepcijske injekcije, obliže in vsadke - rifampicin - za zdravljenje tuberkuloze - varfarin - za preprečevanje in zdravljenje krvnih strdkov v nogah, pljučih, možganih in srcu.
Two litres is a good amount to drink. 
Primerno je, da zaužijete 2 litra tekočine.
Among serious renal-related adverse reactions: renal failure, renal failure acute and renal impairment were reported in 1.9%, 1.9% and 0.9% respectively, of patients receiving lesinurad 400 mg monotherapy and in no patients receiving placebo. 
Med resnimi neželenimi učinki na ledvicah so odpoved ledvic, akutno odpoved ledvic oziroma okvaro ledvic zabeležili pri 1,9 %, 1,9 % oziroma 0,9 % bolnikov, ki so prejemali monoterapijo z lesinuradom in pri nobenem od bolnikov, ki so prejemali placebo.
Zurampic as add-on to allopurinol in inadequate responders CLEAR1 and CLEAR2 enrolled patients with gout who were on a stable dose of allopurinol of at least 300 mg (or 200 mg for moderate renal impairment), had serum uric acid levels greater than 6.5 mg/dL and reported at least 2 gout flares in the previous 12 months. 
Zdravilo Zurampic kot dodatek alopurinolu pri bolnikih z nezadostnim odzivom Študiji CLEAR1 in CLEAR2 sta zajeli bolnike s protinom, ki so dobivali stabilen odmerek vsaj 300 mg alopurinola (oz. 200 mg v primeru zmerne okvare ledvic), so imeli koncentracijo sečne kisline v serumu več kot 6,5 mg/dl in so imeli v preteklih 12 mesecih vsaj 2 napada protina.
Figure 1 Mean serum uric acid levels in pooled clinical studies with Zurampic in combination with allopurinol in patients with inadequate response (sUA ≥6 mg/dL) to allopurinol alone 
Slika 1 Povprečna koncentracija sečne kisline v serumu kumulativno v kliničnih študijah s kombinacijo zdravila Zurampic in alopurinola pri bolnikih, ki se niso zadostno odzvali (SKs ≥ 6 mg/dl) na sam alopurinol
Renal events 
Ledvični dogodki
Zurampic is administered as a 50:50 mixture of lesinurad atropisomers. 
Zdravilo Zurampic se uporablja kot mešanica atropizomerov lesinurada v razmerju 50:50.
You must use Zurampic together with either allopurinol or febuxostat. 
Zdravilo Zurampic morate uporabljati skupaj z alopurinolom ali febuksostatom.
Additional monitoring of lipids and blood pressure is recommended in patients using sensitive CYP3A substrate lipid lowering medicines (such as lovastatin or simvastatin) or antihypertensive medicines (such as amlodipine, felodipine or nisoldipine), since their efficacy may be reduced (see section 4.5). 
Prejemnikom hipolipemikov (npr. lovastatina ali simvastatina) ali antihipertenzivov (npr. amlodipina, felodipina ali nisoldipina), ki so občutljivi substrati CYP3A, je priporočljivo dodatno kontrolirati lipide oz. krvni tlak, ker se njihova učinkovitost lahko zmanjša (glejte poglavje 4.5).
Zurampic in combination with febuxostat in tophaceous gout CRYSTAL enrolled gout patients with measurable tophi. 
Zdravilo Zurampic v kombinaciji s febuksostatom pri tofoznem protinu Študija CRYSTAL je zajela bolnike s protinom, ki so imeli merljive tofe.
Clinical outcomes - tophus resolution and reduction In CRYSTAL, the proportion of subjects who experienced a complete resolution (defined as 100% resolution of at least one target tophus and no single tophus showing progression) of ≥1 target tophus was higher in the group treated with Zurampic 200 mg in combination with febuxostat compared with placebo in combination with febuxostat, although the difference was not statistically different (26% compared with 21%). 
V študiji CRYSTAL je bil delež bolnikov s popolnim izginotjem (opredeljenim kot 100 % izginotje vsaj enega ciljnega tofa in brez napredovanja katerega koli tofa) ≥ 1 ciljnega tofa večji s kombinacijo 200 mg zdravila Zurampic in febuksostata kot s kombinacijo placeba in febuksostata, a razlika ni bila statistično značilna (26 % v primerjavi z 21 %).
Table 3 Proportion of patients with baseline sUA ≥5.0 mg/dLwho achieve target serum uric acid levels (<5 mg/dL) with Zurampic in combination with febuxostat 
Preglednica 3 Delež bolnikov z izhodiščno SKs ≥ 5,0 mg/dl, ki so dosegli ciljno koncentracijo sečne kisline v serumu (< 5 mg/dl) z zdravilom Zurampic v kombinaciji s febuksostatom
Zurampic must not be initiated in patients with severe renal impairment (CrCL less than 30 mL/min), with end-stage renal disease or in patients on dialysis (see sections 4.3 and 4.4). 
Zdravila Zurampic se ne sme uvesti bolnikom s hudo okvaro ledvic (očistek kreatinina manj kot 30 ml/min), končno odpovedjo ledvic in bolnikom na dializi (glejte poglavji 4.3 in 4.4).
Proportion of patients who met serum uric acid target (<6.0 mg/dL) N (%) 
Delež bolnikov, ki so dosegli ciljno vrednost sečne kisline v serumu (< 6,0 mg/dl) N (%)
Renal-related adverse reactions were reported in patients treated with Zurampic 200 mg (5.7%) and Zurampic 400 mg (11.8%) compared to placebo (4.5%), resulting in discontinuation of treatment in 1.2%, 3.3% and 1%, respectively (see section 4.4). 
O neželenih učinkih na ledvicah so poročali pri 5,7 % bolnikov, ki so prejemali 200 mg zdravila Zurampic in 11,8 % bolnikov, ki so prejemali 400 mg zdravila Zurampic v primerjavi s 4,5 % bolnikov, ki so prejemali placebo; ti učinki so povzročili prenehanje zdravljenja pri 1,2 % prvih, 3,3 % drugih in 1 % tretjih (glejte poglavje 4.4).
The efficacy of Zurampic 200 mg and 400 mg once daily was studied in 3 multicentre, randomised, double-blind, placebo-controlled clinical studies in 1,537 adult patients (13% of these patients were elderly, ≥65 years old) with hyperuricaemia and gout in combination with a xanthine oxidase inhibitor, allopurinol (CLEAR1 and CLEAR2) or febuxostat (CRYSTAL). 
Učinkovitost 200 mg in 400 mg zdravila Zurampic enkrat na dan so proučili v 3 multicentričnih, randomiziranih, dvojno slepih, s placebom kontroliranih kliničnih študijah pri 1.537 odraslih bolnikih (13 % bolnikov je bilo starih ≥ 65 let) s hiperurikemijo in protinom.
Atropisomer 1 is extensively metabolised by CYP2C9 whereas atropisomer 2 is minimally metabolised by both CYP2C9 and CYP3A4. 
Atropizomer 1 se izdatno presnavlja s CYP2C9, atropizomer 2 pa se le minimalno presnavlja tako s CYP2C9 kot s CYP3A4.
Rare cases of hypersensitivity (photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria) have been reported with lesinurad during the clinical programme. 
V kliničnem programu so bili med uporabo lesinurada opisani redki primeri preobčutljivosti (fotodermatoza, fotosenzibilnostna reakcija, alergijski dermatitis, srbenje in urtikarija).
Proportion of patients who met serum uric acid Target (<5.0 mg/dL) N(%) 
Delež bolnikov, ki so dosegli ciljno vrednost sečne kisline v serumu (< 5,0 mg/dl) N (%)
Tablet coat hypromellose titanium dioxide triacetin 
Obloga tablete hipromeloza titanov dioksid triacetin indigotin briljantno modro FCF
Patients who are known or suspected to be CYP2C9 poor metabolisers based on previous history or experience with other CYP2C9 substrates should use Zurampic with caution (see section 4.4). 
Zdravilo Zurampic je treba previdno uporabljati pri bolnikih, za katere je na podlagi anamneze ali izkušenj z drugimi substrati CYP2C9 znano ali obstaja sum, da so slabi metabolizatorji s CYP2C9 (glejte poglavje 4.4).
Lesinurad, when combined with a xanthine oxidase inhibitor, increases uric acid excretion and decreases uric acid production resulting in greater sUA lowering. 
Lesinurad v kombinaciji z zaviralcem ksantin-oksidaze poveča izločanje sečne kisline in zmanjša njeno nastajanje ter tako doseže večje znižanje SKs.
Metabolism and nutrition disorders 
Presnovne in prehranske motnje dehidracija
In each of the studies, a greater proportion of patients treated with Zurampic 200 mg in combination with allopurinol compared with placebo in combination with allopurinol achieved a serum uric acid less than 5 mg/dL by Month 6 (CLEAR1: 29% versus 10%; CLEAR2: 35% versus 5%). 
V obeh študijah je koncentracijo sečne kisline v serumu manj kot 5 mg/dl do 6. meseca dosegel večji delež bolnikov, ki so dobivali kombinacijo 200 mg zdravila Zurampic in alopurinola, kot tistih, ki so dobivali kombinacijo placeba in alopurinola (CLEAR1: 29 % v primerjavi z 10 %, CLEAR2: 35 % v primerjavi s 5 %).
Zurampic when added to febuxostat caused an immediate reduction of the mean serum uric acid levels, as compared to placebo, which was sustained in the long term in those patients who continued treatment. 
Febuksostatu dodano zdravilo Zurampic je v primerjavi s placebom povzročilo takojšnje znižanje povprečne koncentracije sečne kisline; pri bolnikih, ki so nadaljevali zdravljenje, je bilo to znižanje stalno in dolgotrajno.
In vitro, lesinurad is an inhibitor of OATP1B1, OAT1, OAT3, OAT4 and OCT1 at clinically relevant plasma concentrations. 
In vitro lesinurad zavira OATP1B1, OAT1, OAT3, OAT4 in OCT1 v plazemskih koncentracijah, ki so klinično pomembne.
Zurampic when added to allopurinol caused an immediate reduction of the mean serum uric acid levels, as compared to placebo, which was sustained in the long term in those patients who continued treatment (see Figure 1). 
Alopurinolu dodano zdravilo Zurampic je v primerjavi s placebom povzročilo takojšnje znižanje povprečne koncentracije sečne kisline; pri bolnikih, ki so nadaljevali zdravljenje, je bilo to znižanje stalno in dolgotrajno (glejte sliko 1).
Zurampic should not be administered with inhibitors of mEH. 
Zdravila Zurampic se ne sme uporabljati z zaviralci mEH.
Metabolites are not known to contribute to the uric acid lowering effects of lesinurad. 
Ni znano, da bi presnovki pripomogli k delovanju lesinurada na znižanje sečne kisline.
Gout flare prophylaxis with colchicine or a nonsteroidal anti-inflammatory drug (NSAID) is recommended for at least 5 months when starting therapy (see section 4.4). 
Na začetku zdravljenja je vsaj 5 mesecev priporočljiva profilaksa napadov protina s kolhicinom ali nesteroidnim protivnetnim zdravilom (NSAID - Non-Steroidal Anti-Inflammatory Drug) (glejte poglavje 4.4).
In the subgroup of patients with a baseline sUA ≥5.0 mg/dL, after 3 weeks of febuxostat therapy, a significant difference was achieved at all study visits for Zurampic 200 mg in combination with febuxostat compared with placebo in combination with febuxostat (see Table 3). 
V podskupini bolnikov z izhodiščno SKs ≥ 5,0 mg/dl (po 3 tednih zdravljenja s febuksostatom) je kombinacija 200 mg zdravila Zurampic in febuksostata v primerjavi s kombinacijo placeba in febuksostata dosegla značilno razliko na vseh obiskih v študiji (glejte preglednico 3).
The most common adverse reaction leading to discontinuation of Zurampic was blood creatinine increased 
Najpogostejši neželeni učinek, ki je povzročil prenehanje zdravljenja z zdravilom Zurampic, je bilo zvišanje kreatinina v krvi (0,8 %).
Although other doses have been studied, the recommended dose of Zurampic is 200 mg once daily in combination with a xanthine oxidase inhibitor. 
Raziskani so bili sicer tudi drugi odmerki zdravila Zurampic, a njegov priporočeni odmerek v kombinaciji z zaviralcem ksantinoksidaze je 200 mg enkrat na dan.
Zurampic must always be taken together with your morning dose of either allopurinol or febuxostat. 
Zdravilo Zurampic morate vedno jemati skupaj z jutranjim odmerkom alopurinola ali febuksostata.
Zurampic should not be initiated in kidney transplant recipients. 
Zdravila Zurampic se ne sme uvesti bolnikom s presajeno ledvico.
CYP2C9 poor metabolisers 
Slabi metabolizatorji s CYP2C9
(200 mg) in patients with mild renal impairment (eCrCL 60 to 89 mL/min), 20% and 73% higher (200 mg) and 3% and 50% higher (400 mg) in patients with moderate renal impairment (eCrCL 30 to 59 mL/min), and 13% higher and 113% higher (400 mg) in patients with severe renal impairment (eCrCL <30 mL/min). 
Po uporabi enkratnega odmerka lesinurada pri bolnikih z okvaro ledvic sta bili Cmax oz. AUC lesinurada v primerjavi s tistima pri normalnem delovanju ledvic: 36 % oz. 30 % večji (200 mg) pri bolnikih z blago okvaro ledvic (ocenjeni očistek kreatinina od 60 do 89 ml/min), 20 % oz. 73 % večja (200 mg) in 3 % oz. 50 % večja (400 mg) pri bolnikih z zmerno okvaro ledvic (ocenjeni očistek kreatinina od 30 do 59 ml/min) ter 13 % večja in 113 % večja (400 mg) pri bolnikih s hudo okvaro ledvic (ocenjeni očistek kreatinina < 30 ml/min).
No overall differences in safety of Zurampic were observed in patients with mild or moderate renal impairment (eCrCL of30-89 mL/min) compared to patients with normal renal function (see sections 4.2 and 5.2). 
Pri bolnikih z blago ali zmerno ledvično okvaro (ocenjeni očistek kreatinina od30 do 89 ml/min) na splošno niso ugotovili razlik v varnosti zdravila Zurampic v primerjavi z bolniki z normalnim delovanjem ledvic (glejte poglavji 4.2 in 5.2).
Each film-coated tablet contains 200 mg lesinurad 
Ena filmsko obložena tableta vsebuje 200 mg lesinurada
Gout flare prophylaxis with colchicine or an NSAID is recommended for at least 5 months when starting Zurampic therapy (see section 4.2). 
Priporočljivo je, da bolnik vsaj 5 mesecev po uvedbi zdravila Zurampic prejema kolhicin ali NSAID za profilakso napadov protina (glejte poglavje 4.2).
Primary end-point in patients with renal impairment Consistent with the overall population, the proportion of patients with mild to moderate renal impairment (eCrCL 30-89 mL/min) who achieved target serum uric acid levels at Month 6 was 56% for Zurampic 200 mg versus 29% for placebo when added to allopurinol, and 40% for Zurampic 200 mg versus 26% for placebo when added to febuxostat in patients with baseline sUA ≥5.0 mg/dL. 
Primarni opazovani dogodek pri bolnikih z okvaro ledvic Tako kot v celotni populaciji je bil delež bolnikov z blago do zmerno okvaro ledvic (ocenjeni očistek kreatinina od 30 do 89 ml/min) in izhodiščno koncentracijo SKs ≥ 5,0 mg/dl, ki so 6. mesec dosegli ciljno koncentracijo sečne kisline v serumu, 56 % z 200 mg zdravila Zurampic in 29 % s placebom po dodatku alopurinolu, oziroma 40 % z 200 mg zdravila Zurampic in 26 % s placebom po dodatku febuksostatu.
In these studies, kidney stone adverse reactions (nephrolithiasis being the most frequent) were reported in patients treated with Zurampic 200 mg (0.6%), Zurampic 400 mg (2.5%) and placebo (1.7%). 
V teh študijah so neželene učinke z ledvičnimi kamni (med njimi je bila najpogostejša nefrolitiaza) zabeležili pri 0,6 % bolnikov, ki so prejemali 200 mg zdravila Zurampic, pri 2,5 % bolnikov, ki so prejemali 400 mg zdravila Zurampic in pri 1,7 % bolnikov, ki so prejemali placebo.
Zurampic 200 mg film-coated tablets 
Zurampic 200 mg filmsko obložene tablete
CYP2C9 inhibitors and inducers 
Zaviralci in induktorji CYP2C9
Serious side effects - Uncommon - may affect up to 1 in 100 people Stop taking Zurampic and see a doctor straight away if you notice any of the following side effects, as these may be signs of a problem with your kidneys - you may need urgent medical treatment: 
Resni neželeni učinki - Občasni: - pojavijo se lahko pri največ 1 od 100 bolnikov Nehajte jemati zdravilo Zurampic in takoj obiščite zdravnika, če opazite katerega od naslednjih neželenih učinkov, kajti to so lahko znaki težav z ledvicami - morda boste potrebovali nujno medicinsko pomoč: - bolečine v ledvenem predelu (pod rebri in nad kolčnico), - slabost v želodcu (siljenje na bruhanje), bruhanje, - spremembe pri uriniranju ali težave z uriniranjem, - utrujenost, slabo počutje ali izgubo apetita.
Each film-coated tablet contains 200 mg of lesinurad. 
Ena filmsko obložena tableta vsebuje 200 mg lesinurada.
Zurampic should be used with caution in patients with a CrCL of 30 to less than 45 mL/min (see section 4.4). 
Pri bolnikih z očistkom kreatinina od 30 do manj kot 45 ml/min je treba zdravilo Zurampic uporabljati previdno (glejte poglavje 4.4).
crospovidone, magnesium stearate - film-coating:hypromellose, titanium dioxide, triacetin, indigo carmine, brilliant blue FCF. 
Druge sestavine so: - Jedro tablete: hipromeloza, mikrokristalna celuloza, laktoza monohidrat (glejte poglavje 2), krospovidon, magnezijev stearat - Filmska obloga: hipromeloza, titanov dioksid, triacetin, indigotin, briljantno modro FCF
DD month YYYY 
DD/MM/LLLL
Zurampic 200 mg film-coated tablets lesinurad 
Zurampic 200 mg filmsko obložene tablete lesinurad
*Photodermatosis, photosensitivity reaction, dermatitis allergic, pruritus and urticaria. 
Preiskave zvišanje kreatinina v krvi *Fotodermatoza, fotosenzibilnostna reakcija, alergijski dermatitis, srbenje in urtikarija **Vključuje prednostne izraze: odpoved ledvic, kronična odpoved ledvic in akutna odpoved ledvic.
Over time, your gout attacks will happen less often if you keep taking Zurampic as advised by your doctor. 
Če boste zdravilo Zurampic še naprej jemali, kot vam je svetoval zdravnik, bodo napadi protina sčasoma postali manj pogosti.
What Zurampic contains - the active substance is lesinurad. 
Kaj vsebuje zdravilo Zurampic Zdravilna učinkovina je lesinurad.
How to take Zurampic 
Kako jemati zdravilo Zurampic
- if you have ‘tumour lysis syndrome' - a fast breakdown of cancer cells which can cause high uric acid levels - if you have ‘Lesch-Nyhan syndrome' -a rare inherited illness that starts in childhood where there is too much uric acid in the blood - if your kidneys work very poorly or you have ‘End-Stage Kidney Disease' - if you have received a kidney transplant - if you are on kidney dialysis. 
- če imate Lesch-Nyhanov sindrom - redko podedovano bolezen, ki se začne v otroštvu in jo spremlja zvišana koncentracija sečne kisline v krvi.
Adverse reactions related to renal function can occur after initiating Zurampic (see section 4.8). 
Po uvedbi zdravila Zurampic se lahko pojavijo neželeni učinki na delovanje ledvic (glejte poglavje 4.8).
In both studies, significantly more patients treated with Zurampic 200 mg in combination with allopurinol achieved the target serum uric acid level of less than 6 mg/dL by Month 6 and by Month 12 compared with patients receiving placebo in combination with allopurinol (see Table 2). 
V obeh študijah je ciljno koncentracijo sečne kisline manj kot 6 mg/dl do 6. in do 12. meseca doseglo značilno več bolnikov, ki so prejemali kombinacijo 200 mg zdravila Zurampic in alopurinola kot bolnikov, ki so prejemali kombinacijo placeba in alopurinola (glejte preglednico 2).
In the pivotal clinical trials, a greater proportion of patients using lipid lowering or antihypertensive medicines that were CYP3A substrates required concomitant medicinal product change when treated with Zurampic 200 mg in combination with a xanthine oxidase inhibitor, compared with patients treated with placebo in combination with a xanthine oxidase inhibitor (35% versus 28%, respectively). 
Zamenjavo sočasnih zdravil je potreboval večji delež bolnikov, ki so obenem jemali kombinacijo 200 mg zdravila Zurampic in zaviralca ksantin-oksidaze, kot tistih, ki so jemali kombinacijo placeba in zaviralca ksantin-oksidaze (35 % prvih in 28 % drugih).
EU/1/15/1080/005 100x1 film-coated tablets (unit dose) 
EU/1/15/1080/005 100x1 filmsko obložena tableta (enoodmerni pretisni omot)
EU/1/15/1080/004 98 film-coated tablets 
EU/1/15/1080/004 98 filmsko obloženih tablet
Pharmacotherapeutic group: Antigout preparations, preparations increasing uric acid excretion ATC code: M04AB05 
Oznaka ATC: M04AB05
Taking this medicine - take in the morning with food and water - takeZurampic at the same time as yourmorning dose of‘xanthine oxidase inhibitor' medicine allopurinol or febuxostat. 
- Zdravilo Zurampic vzemite ob istem času kot jutranji odmerek zdravila, ki zavira ksantin oksidazo - alopurinola ali febuksostata.
Zurampic must be taken together with allopurinol or febuxostat, which are medicines called ‘xanthine oxidase inhibitors' and are also used to treat gout by lowering the amount of uric acid in your blood. 
To sta zdravili, ki zavirata encim ksantin-oksidazo in se prav tako uporabljata za zdravljenje protina, ker zmanjšata količino sečne kisline v krvi.
However, the in vivo activity of OATP1B1, OAT1, OAT3 and OCT1 was not affected by lesinurad. 
Toda in vivo lesinurad ni vplival na aktivnost OATP1B1, OAT1, OAT3 in OCT1.
Gout flares may occur after initiation of therapy with Zurampic. 
Po uvedbi zdravila Zurampic se lahko pojavijo napadi protina.
EU/1/15/1080/003 30 film-coated tablets 
EU/1/15/1080/003 30 filmsko obloženih tablet
A higher incidence of serum creatinine elevations and renal-related adverse reactions including serious adverse reactions was observed with Zurampic 400 mg when given alone or in combination with a xanthine oxidase inhibitor, with the highest incidence when Zurampic was given as monotherapy. 
Med uporabo zdravila Zurampic 400 mg samega ali v kombinaciji z zaviralcem ksantin-oksidaze so opažali večjo incidenco porasta kreatinina v serumu in neželenih učinkov na ledvicah (vključno z resnimi neželenimi učinki); incidenca je bila največja, če je bilo zdravilo Zurampic uporabljeno samostojno (v monoterapiji).
EU/1/15/1080/002 28 film-coated tablets 
EU/1/15/1080/002 28 filmsko obloženih tablet
Zurampic should be interrupted if serum creatinine is elevated to greater than 2 times the pre-treatment value or in case of an absolute serum creatinine value greater than 4.0 mg/dL. 
Uporabo zdravila Zurampic je treba prekiniti, če se kreatinin v serumu zviša na več kot 2-krat tolikšno vrednost, kot je bila pred zdravljenjem, prav tako tudi v primeru absolutne vrednosti kreatinina v serumu nad 4,0 mg/dl. Zdravljenje je treba prekiniti pri bolnikih s simptomi, ki lahko kažejo na akutno urično nefropatijo: npr. z bolečinami v ledvenem predelu, navzeo ali bruhanjem; v tem primeru takoj izmerite kreatinin v serumu.
- each Zurampic 200mg film-coated tablet (tablet) contains 200mg of lesinurad. 
Ena filmsko obložena tableta (tableta) zdravila Zurampic 200 mg vsebuje 200 mg lesinurada.
EU/1/15/1080/001 10 film-coated tablets 
EU/1/15/1080/001 10 filmsko obloženih tablet
Timepoint 
Izhodišče
Zurampic does not need to be discontinued because of a gout flare. 
Zaradi napada protina zdravila Zurampic ni treba prenehati uporabljati.
Cmax and AUC exposures of lesinurad increased proportionally with single doses of lesinurad from 5 to 1,200 mg. 
Cmax in AUC lesinurada sta se povečevali sorazmerno enkratnemu odmerku lesinurada v razponu od 5 do 1200 mg. Na poln želodec je bila geometrična sredina Cmax lesinurada po enkratnem odmerku 200 mg lesinurada 6 µg/ml in geometrična sredina njegove AUC 29 µg/h/ml.
Consistent serum uric acid lowering was observed in patients who were receiving low dose acetylsalicylic acid in the placebo-controlled clinical studies in combination with allopurinol or febuxostat. 
V kliničnih študijah kombinacije z alopurinolom ali febuksostatom, kontroliranih s placebom, so opažali dosledno znižanje sečne kisline pri bolnikih, ki so jemali nizke odmerke acetilsalicilne kisline.
Zurampic 200 mg vs. placebo 
200 mg zdravila Zurampic v primerjavi s placebom
A. 
Sob.
Lesinurad undergoes oxidative metabolism mainly via cytochrome P450 (CYP) 2C9 to intermediate metabolite M3c (not detected in vivo) and is subsequently metabolised by mEH to metabolite M4; there is minimal contribution from CYP1A1, CYP2C19, and CYP3A to the metabolism of lesinurad. 
Lesinurad se presnovi z oksidativno presnovo, predvsem s citokromom P450 (CYP) 2C9, v vmesni presnovek M3c (in vivo ga niso odkrili).
D. 
Ned.
Dehydration 
Odmerjanje
C. 
Čet.
Tell your doctor before taking Zurampic if you have or have had heart failure or other heart problems. 
Če imate ali ste kdaj imeli srčno popuščanje ali druge težave s srcem, morate to povedati zdravniku, preden začnete jemati zdravilo Zurampic.
Monitor for decreased efficacy when Zurampic is co-administered with a CYP2C9 inducer. 
Če je zdravilo Zurampic uporabljeno sočasno s kakšnim induktorjem CYP2C9, bolnika kontrolirajte glede zmanjšane učinkovitosti.